Treating Adults with Type 2 Diabetes | HCP | Trulicity (dulaglutide)
Dulaglutide | CAS#:923950-08-7 | Chemsrc
PDB-101: Global Health: Diabetes Mellitus: About: Timeline
Long Acting GLP-1 Receptor Agonist Drugs Lists and Overview | Biopharma PEG
Dulaglutide - an overview | ScienceDirect Topics
Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program - Jendle -
Battle of GLP-1 delivery technologies - ScienceDirect
CDTL Review and Division Summary Memo for Regulatory Action: Trulicity ( Dulaglutide)
How to Maximize Bioanalytical Performance of Fc-Fusion Proteins: Practical Sample Preparation and LC-MS/MS Workflows for Dulaglutide Quantification from Plasma | Waters
Dulaglutide Drugbank ID : DB ppt download
Dulaglutide For effective diabetes management
MANAGEMENT OF ENDOCRINE DISEASE: Are all GLP-1 agonists equal in the treatment of type 2 diabetes? in: European Journal of Endocrinology Volume 181 Issue 6 (2019)
Signal Peptide Optimization to Prevent N-terminal Truncation of Glucagon Like Peptide-1/IgG-Fc Fusion Protein | SpringerLink
Dulaglutide: Uses, Interactions, Mechanism of Action | DrugBank Online
Glucagon‐Like Peptide‐1 (GLP‐1)‐Based Therapeutics: Current Status and Future Opportunities beyond Type 2 Diabetes - Cheang - 2018 - ChemMedChem - Wiley Online Library
New Approaches to Feline Diabetes Mellitus: Glucagon-like peptide-1 analogs - Chen Gilor, Adam J Rudinsky, Melanie J Hall, 2016
Effects of GLP-1 and Its Analogs on Gastric Physiology in Diabetes Mellitus and Obesity | SpringerLink
Improved glycaemic control and weight loss with once weekly dulaglutide versus placebo, both added to titrated daily insulin glargine in type 2 diabetes patients (AWARD-9) - Media Centre | EASD
Amino acid sequence of glucagon like peptide-1 (GLP-1) and GLP-1... | Download Scientific Diagram
Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study - The Lancet
Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial - The Lancet
Dulaglutide For effective diabetes management
Safety and Efficacy of Dulaglutide, a Once Weekly GLP-1 Receptor Agonist, for the Management of Type 2 Diabetes
Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial - The Lancet Diabetes & Endocrinology